银杏酮酯片治疗非痴呆性血管性认知功能障碍的临床研究

Clinical Observation on Yinxin Tongzhi Tablet in the Treatment of Vascular Cognitive Impairment with Non-Dementia

目的观察银杏酮酯片治疗非痴呆性血管性认知功能障碍(VCIND)的临床疗效,并探讨其作用机制。方法将68例VCIND病人随机分为治疗组与对照组,分别口服银杏酮酯片或安慰剂,每次1片,每日3次,连续服药24周。观察两组治疗前后阿尔茨海默病认知评价量表(ADAS-COG)评分、临床印象变化量表评分(CIBIC-PLUS)与简易智能精神状态检查量表评分(MMSE)、血清白介素-6(IL-6)、白介素-8(IL-8)和肿瘤坏死因子-α(TNF-α)变化。结果治疗24周时,治疗组ADAS-COG评分、CIBIC-PLUS评分以及MMSE评分均明显优于对照组(P<0.05)。对照组第24周ADAS-COG评分、CIBIC-PLUS评分以及MMSE评分与治疗前比较差异有统计学意义(P<0.05);治疗后治疗组IL-6、IL-8、TNF-α均较治疗前显著下降,与对照组比较,治疗组下降更显著,差异有统计学意义(P<0.05)。结论银杏酮酯片能够一定程度上延缓VCIND病人认知障碍的发展,可能通过调节与VCIND相关的炎症因子延缓疾病进展。

Objective To investigate the effect of Yinxin Tongzhi tablet （YTT） in the treatment of vascular cognitive impairment with non-de-mentia （VCIND）. Methods Sixty-eight patients with VCIND two groups：control group treated with placebo,and treatment group （ n=34） treated with YTT for 24 weeks. The changes of Alzheimer’s disease assessment scale （ADAS-COG）,Clinician Interview based Im-pression of Severity （CIBIC-PLUS） and Mini-mental State Examination （MMSE） were evaluated before and after treatment.The lev-els of interleukin-6 （IL-6）,interleukin-8 （IL-8） and tumor necrosis factor-α（TNF-α） were observed. Results After 24 weeks of treatment,the scores of ADAS-COG,CIBIC-PLUS and MMSE were better in treatment group than that in control group （ P〈0.05）. There were significant differences in the scores of ADAS-COG,CIBIC-PLUS and MMSE before and after treatment （ P〈0.05）. After treatment,the levels of IL-6,IL-8,TNF-αwere decreased in treatment group,which were lower than that in control group （P〈0.05）. Conclusion YTT can delay the development of cognitive impairment in patients with VCIND to a certain extent,and may delay the progression by modulating the associated inflammatory factors.